| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.076 | 0.6 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.033 | 0.6 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.062 | 0.6 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.7 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.7 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.021 | 0.7 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.7 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.03 | 0.7 |